Comparative Pharmacology
Head-to-head clinical analysis: COUMADIN versus SODIUM HEPARIN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: COUMADIN versus SODIUM HEPARIN.
COUMADIN vs SODIUM HEPARIN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Inhibits vitamin K epoxide reductase complex 1 (VKORC1), thereby decreasing the synthesis of vitamin K-dependent clotting factors II, VII, IX, and X, as well as anticoagulant proteins C and S.
Binds to antithrombin III, accelerating its inhibition of factor Xa and thrombin (factor IIa), thereby preventing fibrin formation and extension of thrombi.
Initial dose 2-5 mg orally once daily, adjusted based on INR response; typical maintenance dose 2-10 mg/day.
Initial IV bolus 80 units/kg followed by continuous IV infusion at 18 units/kg/hour; adjusted based on aPTT. Alternatively, subcutaneous: 333 units/kg loading dose then 250 units/kg every 12 hours.
None Documented
None Documented
Terminal elimination half-life: 20–60 hours (mean ~40 hours); clinically, anticoagulant effect persists for 2–5 days after stopping due to hepatic synthesis of functional clotting factors.
Terminal elimination half-life is dose-dependent: 0.5-1.5 hours at low doses, 1.5-2.5 hours at high doses. Clinically, anticoagulant effect half-life is approximately 1-5 hours, with shorter half-life at lower doses.
Renal (approximately 92% as inactive metabolites), fecal/biliary (minor, approximately 8%). Less than 2% excreted unchanged.
Renal: negligible; primarily cleared by hepatic and reticuloendothelial system (desulfation and depolymerization). Unchanged drug not excreted in urine.
Category C
Category A/B
Anticoagulant
Anticoagulant